INTRODUCTION
============

Infantile colic (IC) is a frequent and distressing functional disorder which is defined as unsoothable crying for longer than three hours per day, for three or more days per week during at least one week without failure to thrive or any obvious organic cause \[[@B1]\]. Although IC is considered to be a limiting and benign condition, it raises anxiousness and concern for parents and is a frequent reason for parents to seek medical help \[[@B2][@B3][@B4][@B5]\].

The prevalence of IC was reported by Canivet et al. \[[@B6]\] to be within a range of 9% and 60%, while the estimation of an expert group was 17.7% \[[@B7]\]. The pathogenesis of IC remains unknown, but exposure to tobacco smoke is recognized as a potential risk factor \[[@B8]\]. It is hypothesized that immaturity of the nervous or digestive system of the infants is interfere as a risk factor.

Dietary changes may be of some benefit for relief of crying in IC \[[@B9][@B10]\]. The aim of this study was to evaluate the efficacy of a formula containing a partially hydrolyzed whey protein (pWH), reduced lactose content, the probiotic *Bifidobacterium lactis* BB12 and the prebiotic galacto-oligosaccharide (GOS) in formula fed infants suffering from IC. Data from Savino et al. suggested with a comparable formula that this kind of dietary intervention may be of benefit \[[@B11]\]. The formula in the study by Savino and the intervention formula in this trial both contain a pWH, reduced lactose and GOS as prebiotic. The formula in the study by Savino was in addition thickened with cereals, contained fructo-oligosaccharides (FOS), and did not contain probiotics as did the intervention formula in this study.

MATERIALS AND METHODS
=====================

This open study was conducted at the 3rd Pediatric Department of the Hippocration Hospital, Aristotle University, Thessaloniki, from September 2014 to May 2016. The local ethical committee of Aristotle University approved the study protocol (346/20-12-2016). IC was defined as episodes of unsoothable crying for more than three hours a day for at least three days a week since at least one week. Forty full-term infants with an age range of 20 to 60 days suffering from IC without clinical evidence for an organic cause for the crying such as otitis, urine tract infection, constipation, anal fissure, esophagitis, etc. were included. The characteristics of the infants are listed in [Table 1](#T1){ref-type="table"}. Exclusion criteria were besides an obvious organic cause for the crying, insufficient weight gain (\<150 g/week) and/or presenting with blood in the stools.

When an infant met the inclusion criteria, parents were invited to participate in the study and had to give their written consent before the infant could be included. Infants were included consecutively: for every two infants receiving the intervention formula, one infant was included in the control group, according to the recommendations, reassurance and anticipatory guidance \[[@B11]\]. The intervention formula ([Table 2](#T2){ref-type="table"}: composition on the intervention formula) needed for one month was given to the parents. Feeding in the control group consisted of any regular starter infant formula available on the Greek market. The control group received no medication, food supplement or probiotic.

Parents were asked to assess their infants at inclusion and at the end of the one month intervention. Duration of crying was the primary outcome ([Table 3](#T3){ref-type="table"}). Each assessment at the start and end of the study was done over a period of seven consecutive days: before the intervention formula was given, or the standard starter formula was continued, and during the fourth week after the start of dietary intervention.

All parents were asked to complete the parent form of a quality of life (QoL) questionnaire consisting of seven items regarding symptom duration and frequency, emotions, activities and different aspects related to the management of an infant suffering IC. The scale assesses the burden of IC on a scale ranging from 1 to 5 (very low burden=1 to extremely heavy burden=5). More specifically, the questions addressed the following domains: i) every day QoL, ii) sleep quality, iii) work-related QoL, iv) parent-child relationship, v) stress during everyday life, vi) QoL regarding social interaction with friends and relatives, and vii) overall QoL ([Table 3](#T3){ref-type="table"}). In addition, parents had to record information regarding defecation frequency and composition ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Stool composition was assessed by using a scale from 1 to 5 (hard=1; tight=2, creamy=3, loose=4, watery= 5). During the follow-up visit after one month the parents were asked to rate the evolution during the intervention by selecting one of the following options: a) very important benefit=1, b) important benefit= 2, c) moderate benefit=3, d) very small benefit= 4, and e) no benefit=5.

The non-parametric Wilcoxon test was used to investigate statistically significance of differences in scores between infants in the intervention and control groups at two time points, at inclusion and after one month intervention. t-test (paired and two-sample) was used in order to compare continuous variables between infants in the intervention and control groups, when normality assumption was not violated. Score changes between the intervention and the control group were compared. The non-parametric Mann-Whitney test was used in order to compare score changes between two independent samples based on the variable type. All tests were two-sided and the level of significance was set at 0.05. IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA) was used for the statistical analysis of data.

RESULTS
=======

The infants in the control group were slightly older than these in the intervention group ([Table 1](#T1){ref-type="table"}). AT inclusion, the duration of crying between both groups did not differ. Weight gain in the intervention and control group was comparable. Crying time decreased in the intervention group from 3.2 hours (interquartile range \[IQR\], 3.1--3.3) to 0.5 hours (IQR, 0.3--0.8) ([Table 3](#T3){ref-type="table"}). Although the decrease in crying time was also significant in the control group, the difference in decrease of crying time between the intervention and control group was statistically significant (1.5 hours difference) ([Table 4](#T4){ref-type="table"}).

Median scores of the QoL questionnaire obtained at inclusion decreased after one month in both the intervention and the control group for the majority of the variables indicating improvement. More specifically, in the intervention group median scores improved significantly for all parameters. In the control group, all parameters improved as well except for the parent-child interaction and QoL related social interaction with friends and relatives.

Stool composition became looser only in the intervention group. Defecation frequency showed no statistically significant change in either group ([Table 4](#T4){ref-type="table"}).

The median score changes for all the 7 QoL questionnaire variables between inclusion and after one month was significantly greater in the intervention compared to the control group ([Table 4](#T4){ref-type="table"}). The median score regarding the benefit of intervention versus no intervention was also statistically significantly lower, i.e., better, in the intervention group ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}).

DISCUSSION
==========

A formula containing a pWH, reduced lactose and supplemented with *B. lactis* BB12 and GOS improved significantly QoL and decreased duration of crying time in infants with IC. The literature suggesting benefit of pain-relieving agents in the treatment of IC is sparse and mod tog the time negative \[[@B12]\]. Although simethicone is popular, there are no data suggesting benefit in IC \[[@B12]\]. Also data on the efficacy of herbal agents, sugar, dicyclomine and cimetropium bromide in IC are either limited (as for some herbal agents) or not existing \[[@B12]\]. Cimetropium bromide and simethicone were less effective than a thickened pWH with reduced lactose and prebiotics \[[@B13]\].

The role of lactose in the pathophysiology of IC is debated. The absence of lactose in infant formula does not affect normal growth and may result in less regurgitation and softer stools \[[@B14]\]. A transient low lactase activity has been proposed to trigger excessive crying in infants \[[@B10][@B15]\]. Lactose-free or soy based infant formulae were not consistently reported as beneficial in IC. Lactase or placebo was administered to a small group of infants (n=12) within 5 minutes of breastfeeding in a double-blind, placebo-controlled crossover trial \[[@B16]\]. Compared to placebo, lactase had no significant effect on the duration of crying and fussing \[[@B16]\]. In another double-blind, placebo-controlled crossover trial in 13 infants, lactase reduced crying time with 1.14 hours per day \[[@B17]\]. Selection of patients is likely to be a major bias in most studies. After some initial enthusiasm negative reports resulted a minor role for lactase in IC \[[@B10]\]. In prevention, a formula containing a stable lactase as the result of a fermentation process indicated a decreased incidence of infant crying at the age of four weeks \[[@B18]\]. Although the NICE guidelines (UK-recommendation) suggest a one-week trial of lactase drops in breastfed and formula-fed infants, the evidence for this recommendation is limited \[[@B19]\].

Hydrolyzed protein may also be beneficial in the management of IC. An extensive casein hydrolysate reduced the duration of crying in 15/22 infants \[[@B20]\]. A double-blind challenge test with placebo or capsules containing whey milk powder was positive in 11/15 infants \[[@B20]\]. Similar results, a decrease of crying time with 63 minutes, have been reported with an extensive whey hydrolysate \[[@B21]\]. Crying duration deceased with 45% in a small group of infants with IC (n=6) fed an amino acid based formula \[[@B22]\]. A challenge with 75 mg of bovine immunoglobulin G resulted in an increase of crying and fussing behavior \[[@B22]\].

Several studies have assessed the effect of probiotics in the management of IC. Different studies provided sufficient evidence to conclude in meta-analyses that *Lactobacillus reuteri* DSM 17938 at a dose of 10^8^ colony-forming units per day in breastfed infants decreased IC and was well tolerated and safe \[[@B23][@B24]\], resulting in a reduction of parental discomfort and the number of consultations \[[@B13]\]. One study in mainly formula fed infants with the same *L. reuteri* strain yielded a negative result \[[@B25]\]. At least two trials with *L. rhamnosus* in infants with IC were negative \[[@B26][@B27]\]. Infants fed *B. lactis* and *Streptococcus thermophilus* reported a significantly lower incidence of IC or irritability than the placebo group \[[@B28]\]. However, there was no significant difference in episodes of fever, loose stools and vomiting, or discomfort passing bowel movements and daycare absenteeism \[[@B28]\]. However, antibiotics were significantly less used in both probiotic groups than in the placebo group \[[@B29]\]. The duration of crying in our study in the intervention group receiving a formula supplemented with the probiotic *B. lactis* decreased from over 3 hours to less than one hour daily. The reduction of the duration of crying was also noted in the control group, but the effect in the probiotic group was much more pronounced.

A few studies evaluated the efficacy of prebiotics in the management of IC. A pWH supplemented with FOS and GOS resulted in a reduction of crying episodes in infants with IC after 1 and 2 weeks in comparison with a standard formula and simethicone \[[@B30]\]. The same formula was previously evaluated in an open study and did show a reduction of colic and of feeding problems such as regurgitation and defecation problems \[[@B29]\]. A GOS-supplemented formula mimicked the effect of human milk on the gastro-intestinal microbiome promoting *Bifidobacterium* and *Lactobacillus* growth and inhibiting *Clostridium* growth, resulting in a significantly lower prevalence of IC \[[@B31]\].

A major shortcoming is that the present study is an open-labeled trial in which the control group differed at baseline from in the intervention group. The control group was 0.4 months older than the intervention group. However, the difference favors the control group as IC tends to decrease spontaneously over time. Since the difference in median age of inclusion is only twee weeks, with a median age of 1 month in the intervention group and 1.4 months in the control group, it is unlikely that the control group suffered more severe symptoms as the age at which spontaneous decrease starts is 3 months. Moreover, it is virtually impossible to blind studies with infant formula as the formulas that are compared often have differences in texture, smell and taste. Also, this was not a classically randomized trial. Although by applying a consecutive allocation sequence of "two infants intervention formula-one infant standard infant formula" a bias-risk induced by selection of patients was minimized. Another limitation of the present clinical trial is that the data rely on subjective observations made by the parents. Future clinical trials should benefit from more objective observations, such as computer recording of crying episodes, and therefore provide a more precise and reliable way of evaluating IC. Moreover, in this study -as in other studies evaluating a formula change- several interventions are evaluated concomitantly. As a consequence, the effectiveness of each intervention on itself is not known. Furthermore, the bias risk of the study is high as the study was open.

In conclusion, this clinical trial supports the beneficial effects of a formula with a partial whey hydrolysate, reduced lactose, supplemented with a probiotic (*B. lactis*) and prebiotic (GOS) for IC in formula-fed infants. These data need to be confirmed by a double-blind, prospective, randomized trial.

This study has been supported by Rontis, providing free formula in the intervention group for the study period. Yvan Vandenplas has participated as a clinical investigator, and/or advisory board member, and/or consultant, and/or speaker for Abbott Nutrition, Aspen, Biogaia, Biocodex, Danone, Hero, Kabrita, Nestle Nutrition Institute, Nutricia, Mead Johnson Nutrition, Merck, Olygose, Orafti, Phacobel, Rontis, Sari Husada, United Pharmaceuticals, Wyeth and Yakult. The co-authors did not report any potential COI.
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Values are presented as mean±standard deviation.

^\*^t-test.

###### Composition of the Intervention Formula (per 100 mL)

![](pghn-20-100-i002)

###### Median Scores of the Quality of Life (QoL) Variables in the Intervention and the Control Group, Stool Composition and Frequency at Inclusion and after One Month Intervention
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Values are presented as median (interquartile range, IQR) or mean±standard deviation.

^\*^Wilcoxon test, ^†^t-test.

###### The Median Score Changes for All the Quality of Life (QoL) Variables Stool Composition and Frequency between the First and Second Month following the Intervention
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Values are presented as median (interquartile range, IQR).

^\*^Mann-Whitney test.
